Zhang Xiuling, Li Ping, Rong Minhua, He Rongquan, Hou Xinxi, Xie You, Chen Gang
Department of Pathology, First Affiliated Hospital of Guangxi Medical University.
Tohoku J Exp Med. 2015 Mar;235(3):161-9. doi: 10.1620/tjem.235.161.
Lung cancer is the most common malignant tumor worldwide. MicroRNA has become an ideal biomarker for cancer diagnosis, prognosis and therapy. The relationship between microRNA-141 and non-small cell lung cancer (NSCLC) is contradictory. Thus, in current study, we aimed to investigate the level of microRNA-141 in NSCLC tissues and to evaluate its potential clinical value. This study enrolled 125 NSCLC patients (75 males and 50 females) with a median age of 61 years (range, 23-90 years). NSCLC patients included 23 squamous cell carcinomas (SCCs), 101 adenocarcinomas (ADCs) and 1 large cell carcinoma. The expression level of microRNA-141 was significantly higher in NSCLC tissues than in adjacent lung tissues (P < 0.001), detected by real time RT-PCR. Receiver operating characteristic (ROC) exhibited a moderate diagnostic value of microRNA-141 for NSCLC with the area under curve of 0.707. The microRNA-141 expression increased with the larger tumor size (P = 0.002), lymph node metastasis (P = 0.018) and advanced stage (P = 0.022) in NSCLC patients. For subgroup analysis, microRNA-141 expression in SCC was correlated with tumor size (r = 0.490, P = 0.018), and in ADC, microRNA-141 level was positively associated with tumor size (r = 0.222, P = 0.026), lymph node metastasis (r = 0.242, P = 0.015) and TNM stage (r = 0.210, P = 0.035). Furthermore, univariate analysis revealed that the expression of microRNA-141 was an independent prognostic indicator of ADC. In conclusion, microRNA-141 is a potential biomarker for the molecular diagnosis and risk stratification of NSCLC.
肺癌是全球最常见的恶性肿瘤。微小RNA已成为癌症诊断、预后及治疗的理想生物标志物。微小RNA - 141与非小细胞肺癌（NSCLC）之间的关系存在矛盾。因此，在本研究中，我们旨在探究NSCLC组织中微小RNA - 141的水平，并评估其潜在的临床价值。本研究纳入了125例NSCLC患者（男性75例，女性50例），中位年龄为61岁（范围23 - 90岁）。NSCLC患者包括23例鳞状细胞癌（SCC）、101例腺癌（ADC）和1例大细胞癌。通过实时逆转录聚合酶链反应检测发现，NSCLC组织中微小RNA - 141的表达水平显著高于相邻肺组织（P < 0.001）。受试者工作特征（ROC）曲线显示微小RNA - 141对NSCLC具有中等诊断价值，曲线下面积为0.707。在NSCLC患者中，微小RNA - 141的表达随肿瘤体积增大（P = 0.002）、淋巴结转移（P = 0.018）及分期进展（P = 0.022）而升高。亚组分析显示，SCC中微小RNA - 141的表达与肿瘤大小相关（r = 0.490，P = 0.018），在ADC中，微小RNA - 141水平与肿瘤大小（r = 0.222，P = 0.026）、淋巴结转移（r = 0.242，P = 0.015）及TNM分期（r = 0.210，P = 0.035）呈正相关。此外，单因素分析显示微小RNA - 141的表达是ADC的独立预后指标。总之，微小RNA - 141是NSCLC分子诊断及风险分层的潜在生物标志物。
